The drugmaker is counting on upcoming medicine launches to spur sales growth next year and beyond, as it works to secure approvals for new breast-cancer and multiple-sclerosis pills.
The drugmaker is counting on upcoming medicine launches to spur sales growth next year and beyond, as it works to secure approvals for new breast-cancer and multiple-sclerosis pills.